JP2022551256A5 - - Google Patents
Info
- Publication number
- JP2022551256A5 JP2022551256A5 JP2022520238A JP2022520238A JP2022551256A5 JP 2022551256 A5 JP2022551256 A5 JP 2022551256A5 JP 2022520238 A JP2022520238 A JP 2022520238A JP 2022520238 A JP2022520238 A JP 2022520238A JP 2022551256 A5 JP2022551256 A5 JP 2022551256A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- substituted
- alkyl
- pharmaceutical composition
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962908677P | 2019-10-01 | 2019-10-01 | |
| US62/908,677 | 2019-10-01 | ||
| US201962924781P | 2019-10-23 | 2019-10-23 | |
| US62/924,781 | 2019-10-23 | ||
| US202062967761P | 2020-01-30 | 2020-01-30 | |
| US62/967,761 | 2020-01-30 | ||
| PCT/IB2020/059101 WO2021064570A1 (en) | 2019-10-01 | 2020-09-29 | N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551256A JP2022551256A (ja) | 2022-12-08 |
| JP2022551256A5 true JP2022551256A5 (enExample) | 2023-10-10 |
Family
ID=72811912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520238A Pending JP2022551256A (ja) | 2019-10-01 | 2020-09-29 | ヒト免疫不全ウイルスの複製阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220409619A1 (enExample) |
| EP (1) | EP4038064B1 (enExample) |
| JP (1) | JP2022551256A (enExample) |
| ES (1) | ES2974657T3 (enExample) |
| WO (1) | WO2021064570A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11541055B2 (en) | 2018-10-24 | 2023-01-03 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121335877A (zh) | 2023-06-15 | 2026-01-13 | Viiv保健英国第五有限公司 | 用于制备化合物的方法和中间体 |
| TW202547514A (zh) | 2024-02-05 | 2025-12-16 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| ES2642265T3 (es) | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| EP3186239B1 (en) | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| CN119462611A (zh) * | 2016-08-19 | 2025-02-18 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| JP7083398B2 (ja) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジン誘導体およびｈｉｖ感染を処置するためのその使用 |
| EP3752496B1 (en) | 2018-02-16 | 2023-07-05 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
-
2020
- 2020-09-29 EP EP20789276.1A patent/EP4038064B1/en active Active
- 2020-09-29 JP JP2022520238A patent/JP2022551256A/ja active Pending
- 2020-09-29 ES ES20789276T patent/ES2974657T3/es active Active
- 2020-09-29 US US17/763,317 patent/US20220409619A1/en not_active Abandoned
- 2020-09-29 WO PCT/IB2020/059101 patent/WO2021064570A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022551256A5 (enExample) | ||
| JP7641388B2 (ja) | 一連のピペリジン置換安息香酸系化合物及びその使用 | |
| CN109803967B (zh) | 二氢嘧啶类化合物及其制备方法和用途 | |
| CA3142069A1 (en) | Aurora kinase inhibitor and use thereof | |
| CN112771027A (zh) | 溶血磷脂酸受体拮抗剂及其制备方法 | |
| EP3102572A1 (en) | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| CA2881322A1 (en) | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| JP2003535860A (ja) | 新規なオキサゾリジノン誘導体及びその製造方法 | |
| CN102112453A (zh) | 新的钾通道阻断剂及其用途 | |
| TW201625581A (zh) | 側氧雜環衍生物 | |
| JP2023513419A (ja) | オーロラａ選択的阻害剤として有用な新規複素環式化合物 | |
| KR20190129034A (ko) | 금속효소 억제제 화합물 | |
| CA2938703A1 (en) | Substituted thiazole or oxazole p2x7 receptor antagonists | |
| JP2023517043A5 (enExample) | ||
| EA031614B1 (ru) | Трициклические атропоизомерные соединения | |
| TW202102474A (zh) | 吡咯化合物 | |
| JP2022551254A5 (enExample) | ||
| AU2004226207A1 (en) | 4-substituted quinolein derivatives with antimicrobial activity | |
| JP2024514251A (ja) | 二環式化合物の製造方法及び抗菌剤としての使用 | |
| CN112236424A (zh) | 经烷氧基取代的吡啶基衍生物 | |
| JP2008504351A (ja) | ４−置換キノリン誘導体、その製造方法およびそのための中間体、ならびにこれを含む医薬組成物 | |
| CN112898316A (zh) | 新型吡咯化合物 | |
| JP7168245B2 (ja) | 三環式化合物 | |
| JP2022541772A (ja) | インターロイキンの調節におけるプロドラッグ | |
| EP3743419B1 (en) | Novel compounds for the treatment of parasitic infections |